Trial · NCT02342886
Participant flow25
How many started, completed or left each group, period by period.
1 to 20 of 25
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide | 65 | |
| Overall Study | STARTED | DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | 71 | |
| Overall Study | STARTED | DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | 67 | |
| Overall Study | STARTED | DS-TB: 2 Months HRZE / 4 Months HR | 68 | |
| Overall Study | STARTED | MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | 13 | |
| Overall Study | Completed Month 12 Follow-Up | DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide | 43 | |
| Overall Study | Completed Month 12 Follow-Up | DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | 52 | |
| Overall Study | Completed Month 12 Follow-Up | DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | 49 | |
| Overall Study | Completed Month 12 Follow-Up | DS-TB: 2 Months HRZE / 4 Months HR | 57 | |
| Overall Study | Completed Month 12 Follow-Up | MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | 10 | |
| Overall Study | Completed Month 24 Follow-Up | DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide | 40 | |
| Overall Study | Completed Month 24 Follow-Up | DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | 47 | |
| Overall Study | Completed Month 24 Follow-Up | DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | 46 | |
| Overall Study | Completed Month 24 Follow-Up | DS-TB: 2 Months HRZE / 4 Months HR | 53 | |
| Overall Study | Completed Month 24 Follow-Up | MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | 10 | |
| Overall Study | COMPLETED | DS-TB: 4 Months Moxifloxacin + PA-824 (100 mg) + Pyrazinamide | 57 | |
| Overall Study | COMPLETED | DS-TB: 4 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | 63 | |
| Overall Study | COMPLETED | DS-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | 52 | |
| Overall Study | COMPLETED | DS-TB: 2 Months HRZE / 4 Months HR | 59 | |
| Overall Study | COMPLETED | MDR-TB: 6 Months Moxifloxacin + PA-824 (200 mg) + Pyrazinamide | 10 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02342886/flow